P
Phillippe Gabriel Steg
Researcher at University of Paris
Publications - 116
Citations - 9028
Phillippe Gabriel Steg is an academic researcher from University of Paris. The author has contributed to research in topics: Myocardial infarction & Acute coronary syndrome. The author has an hindex of 45, co-authored 116 publications receiving 8347 citations. Previous affiliations of Phillippe Gabriel Steg include Katholieke Universiteit Leuven & French Institute of Health and Medical Research.
Papers
More filters
Journal ArticleDOI
Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes.
Ziad Mallat,Benamer H,Bénédicte Hugel,Joelle Benessiano,Phillippe Gabriel Steg,Freyssinet Jm,Alain Tedgui +6 more
TL;DR: High levels of procoagulant endothelial microparticles are present in the circulating blood of patients with ACS and may contribute to the generation and perpetuation of intracoronary thrombi.
Journal ArticleDOI
Management of acute coronary syndromes. Variations in practice and outcome. Findings from the Global Registry of Acute Coronary Events (GRACE)
Keith A.A. Fox,Shaun G. Goodman,Werner Klein,D. Brieger,Phillippe Gabriel Steg,Omar H. Dabbous,A Avezum +6 more
TL;DR: The GRACE study reveals substantial differences in the management of patients based on hospital type and geographical location and will determine whether such variations translate into differences in longer term outcomes.
Journal ArticleDOI
Determinants and prognostic impact of heart failure complicating acute coronary syndromes: observations from the Global Registry of Acute Coronary Events (GRACE).
Phillippe Gabriel Steg,Omar H. Dabbous,Laurent J. Feldman,Alain Cohen-Solal,Marie-Claude Aumont,Jose Lopez-Sendon,Andrzej Budaj,Robert J. Goldberg,Werner Klein,Frederick A. Anderson +9 more
TL;DR: In this observational registry, heart failure was associated with reduced hospital and 6-month survival across all ACS subsets, including patients with normal markers of necrosis, and more aggressive treatment of these patients may be warranted to improve prognosis.
Journal ArticleDOI
PexeLizumab for Acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: A randomized controlled trial
Paul W. Armstrong,N. Bett,David Brieger,D. Chew,R. Dick,A. Farshid,P Garrahy,B. Gunalingham,R. Hendriks,John D. Horowitz,Nigel Jepson,Jeffrey Lefkovits,S. Lo,Ian T. Meredith,G. Nelson,G. New,Ananth M. Prasan,J. Rankin,P. Thompson,S. Worthley,R. Yadav,Kurt Huber,Gerald Maurer,P. Siostrzonek,J. Boland,C. Covens,Walter Desmet,K. Dujardin,M. Vrolix,Christopher E. Buller,P. Klinke,C. Lazzam,Sohrab Lutchmedial,Mina Madan,Madhu K. Natarajan,François Reeves,J. Rodes Cabau,Barry Rose,Erick Schampaert,Pierre Theroux,Mouhieddin Traboulsi,John G. Webb,Robert C. Welsh,R. Zimmerman,M. Aschermann,M. Branny,T. Budesinsky,P. Cervinka,H. Frantisek,T. Frantisek,L. Groch,P. Kala,M. Ritcher,R. Rokyta,J. St'asek,R. Stipal,I. Varvarovsky,D. Zamanek,M. Zelizko,T. Toftegaard Nielsen,K. Rasmussen,P. RiisHansen,P. Thayssen,P. Beaufils,P. Geslin,Y. Gottwalles,H. Lebreton,H. LeMarec,Gilles Montalescot,G. Roul,Phillippe Gabriel Steg,C. Tronc,H. J. Berger,Martin Borggrefe,J. Brachmann,P. Braun,M. Buerke,H. R. Figulla,H. Guelker,G. Hasenfuss,T. Heitzer,Hubertus Heuer,E. Hoffman,S. Hoffmann,K. H. Kuck,Franz-Josef Neumann,J. Neuzner,M. Rau,G. Richardt,Heribert Schunkert,R. Stern,W. Von Schedit,P. C. Werner,R. Zahn,G. Binetti,E. Bramucci,G. Carosio,A. Manari,A. Marzocchi,M. Medda,G. Piovaccari,Alessandro Politi,L. Vignali,R. Violini,M. Zanchetta,R. Zanini,K. Marques,H. Otto Peels,T. Slagboom,P. C. Smits,Harry Suryapranata,M. J. Suttorp,M. Van-DerEnt,I. Crozier,G. Devlin,Sian E. Harding,Harvey D. White,G. Wilkins,M. Krzeminska-Pakula,K. Loboz-Grudzien,W. Ruźyllo,W. Tracz,M. Trusz-Gluza,M. Almeida,J. Correiada Cunha,P. Farto Abreu,L. Mourão,H. Pereira,L. Providencia,R. Vascoda Gama,A. Bertriu,C. Cuellas,E. Esplugas,E. Garcia Fernandez,X. Goicolea,J. M. Hernandez,C. Macaya,V. Mainar,Angel Martínez Sánchez,P. Erikksson,Stefan James,G. Olivercrona,C. M. Pripp,E. Camenzind,M Pfisterer,M. Pieper,Hans Rickli,R. Acheatel,A. Ahmad,A. Albirini,R. Allen,A. Amkieh,H. V. Anderson,J. Anderson,B. Armstrong,W. Asfour,T. Ayres,M. Azrin,Z. Baber,L. Barr,G. Barsness,J. Batty,Mahesh Bikkina,James C. Blankenship,Duncan J. Campbell,P. Caples,T. Carlson,John C. Chambers,H. Chandna,B. Cheek,J. Cheirif,A. Chu,H. Colfer,B. Crenshaw,S. David,A. DeFranco,J. Dehoya,J. Diez,G. Eaton,E. Eichhorn,M. El Shahawy,T. Farah,W. Felten,D. Fortuin,Malcolm T. Foster,D. S. Gantt,J. Gard,M. Ghali,R. Glaser,M. Greenberg,John H. Griffin,G. Hanovich,N. Hassinger,S. Heifetz,Timothy D. Henry,J. Hermiller,J. Hernandez,R. Hodson,M. Imburgia,B. Iteld,Z. Jafar,A. Jain,N. Jamal,G. Kang,Ronald P. Karlsberg,S. Khanal,S. Khoury,J. Kieval,Robert Kipperman,Robert Kipperman,B. Kluck,David F. Kong,E. Kosinski,M. Kozak,H. Kozman,P. Kraft,A. Labroo,P. Lai,N. Lakkis,G. Lane,B. Laretta,D. Lee,M. Leesar,J. Leggett,M. Levine,S. Lieberman,M. Lim,J. Luber,V. Marques,K. Marzo,J. McGarvey,G. McKendall,B. McLellan,M. Meengs,D. Mego,A. Mehra,J. A. Messenger,J. O. Messenger,M. Midei,Matthew R. Miller,David J. Moliterno,K. Momah,M. Mowdy,A. Nahhas,J. Navas,A. Niederman,T. Nygaard,William W. O'Neill,Kunal Patel,S. Pfau,V. Pompili,D. Purdy,B. Reddy,Alan Rees,J. Reiner,A. Riba,E. Rivera,David T. Roberts,A. Rosenblatt,W. Rowe,S. Rowley,D. Rubin,K. Saeian,Frank S. Saltiel,S. Sample,B. Sanchez,I. Sarembock,Jorge F. Saucedo,T. Schreiber,Ranjit Shah,M. Singh,J. Slater,R. Small,C. Staniloae,P. S. Sundram,L. Swenson,G. Symkoviak,K. Tam,A. Taussig,J. Thatcher,P. Tolerico,J. Trippi,S. Turk,K. Van Osdol,R. Vicari,A. Virmani,M. Warner,R. Webel,J. Wertheimer,G. Williams,Jonathan H. Williams,M. Winniford,D. Wohns,D. X.M. Zhao +293 more
TL;DR: In this large clinical trial of patients treated with primary PCI for STEMI, mortality was low and unaffected by administration of pexelizumab, and the composite end points of death, shock, or heart failure were similar.
Journal ArticleDOI
Expert Consensus Document on the Use of Antiplatelet Agents The Task Force on the Use of Antiplatelet Agents in Patients with Atherosclerotic Cardiovascular Disease of the European Society of Cardiology
C Patrono,Fedor Bachmann,Colin Baigent,C. Bode,R. De Caterina,Bernard Charbonnier,Desmond J. Fitzgerald,Jack Hirsh,Steen Elkjær Husted,J Kvasnicka,Gilles Montalescot,L. A. Garcia Rodriguez,F.W. Verheugt,Jozef Vermylen,Lars Wallentin,Silvia G. Priori,M A Alonso Garcia,Jean-Jacques Blanc,A Budaj,Martin R. Cowie,Veronica Dean,J.W. Deckers,E Fernández Burgos,John Lekakis,Bertil Lindahl,G. Mazzotta,João Morais,Ali Oto,Otto A. Smiseth,Rafael Ferreira,Phillippe Gabriel Steg,F Teixeira,Robert G. Wilcox +32 more
TL;DR: It is of great importance that guidelines and recommendations are presented in formats that are easily interpreted, and whether guidelines improve the quality of clinical practice and the utilization of health resources is investigated.